234 related articles for article (PubMed ID: 37884970)
21. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer.
Liu H; Zhou L; Cheng H; Wang S; Luan W; Cai E; Ye X; Zhu H; Cui H; Li Y; Chang X
Chin Med J (Engl); 2023 Dec; 136(24):2974-2982. PubMed ID: 37284741
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.
Dai D; Li Q; Zhou P; Huang J; Zhuang H; Wu H; Chen B
Front Cell Dev Biol; 2022; 10():874588. PubMed ID: 35769257
[TBL] [Abstract][Full Text] [Related]
23. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
25. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
26. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
Wang L; Li X
Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
Zhang F; Liu Y; Yang Y; Yang K
BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
[TBL] [Abstract][Full Text] [Related]
28. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer.
Yu D; Luo Y; Guo R; Ma F; Chang Y; Dang J
J Gene Med; 2024 May; 26(5):e3686. PubMed ID: 38689382
[TBL] [Abstract][Full Text] [Related]
31. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
Yue C; Ma H; Zhou Y
PeerJ; 2019; 7():e8128. PubMed ID: 31803536
[TBL] [Abstract][Full Text] [Related]
33. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
Xu Y; Tan S; Huang W; Wang YX
Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
[TBL] [Abstract][Full Text] [Related]
34. Assessing of programmed cell death gene signature for predicting ovarian cancer prognosis and treatment response.
Lian X; Liu B; Wang C; Wang S; Zhuang Y; Li X
Front Endocrinol (Lausanne); 2023; 14():1182776. PubMed ID: 37342266
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
36. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
37. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
39. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.
Liu Z; Liu H; Wang Y; Li Z
BMC Gastroenterol; 2022 Oct; 22(1):435. PubMed ID: 36241983
[TBL] [Abstract][Full Text] [Related]
40. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
Yan C; Liu Q; Jia R
Front Oncol; 2022; 12():829045. PubMed ID: 35186763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
